← Back to headlines
Piper Sandler Raises AbbVie Price Target on IBD Pipeline Progress
Piper Sandler has increased its price target for AbbVie, citing significant progress in the company's inflammatory bowel disease (IBD) drug pipeline.
27 May, 10:27 — 27 May, 10:27
Sources
Showing 1 of 1 sources
